Chronic Hepatitis B Virus: What an Internist Needs to Know: Serologic Diagnosis, Treatment Options, and Hepatitis B

Peter D Block1, Joseph K Lim2

  • 1Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA.

Insights

Chronic hepatitis B virus (HBV) infection impacts millions globally, leading to severe liver disease. Antiviral therapies can suppress viral replication and reduce the risk of liver events in patients with active infections.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Chronic hepatitis B virus (HBV) infection affects 292 million worldwide and 1.6 million in the U.S.
  • HBV is linked to significant morbidity and mortality from cirrhosis and hepatocellular carcinoma.
  • Disproportionately affects individuals from HBV-endemic regions like sub-Saharan Africa and the Asian-Pacific.

Purpose of the Study:

  • To summarize the diagnosis and treatment of chronic HBV infection.
  • To highlight the impact of antiviral therapy on liver events.

Main Methods:

  • Diagnosis confirmed by positive HBsAg and detectable HBV DNA.
  • Treatment considered for patients with immunoactive disease (elevated HBV DNA and serum ALT).

Main Results:

  • Antiviral therapies include peg-interferon or oral nucleos(t)ide analogues.
  • These treatments suppress HBV viral replication.
  • Associated with a decreased risk for liver events such as cirrhosis and hepatocellular carcinoma.

Conclusions:

  • Chronic HBV is a major global health concern requiring effective management.
  • Antiviral therapy is crucial for controlling viral load and preventing severe liver complications.
  • Early diagnosis and treatment can mitigate the long-term consequences of HBV infection.